JANX Janux Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$16,93
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$12,4252-Wochen-Tief
$35,3452-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1.03B
P/E (TTM)
-10.3
EPS (TTM)
$-1.64
Umsatz (TTM)
$24M
Ihre Abzeichen
52W-Spanne
$12–$35
Analystenbewertung
BUY
Kursziel
$36
P/E
-10.3
ROE
-10.7%
Nettogewinnmarge
-427.5%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
JANX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$16.93
Marktkapitalisierung (MRQ)
$1.03B
P/E (TTM)
-10.3
EPS (TTM)
$-1.64
Umsatz (TTM)
$24M
ROE (TTM)
-10.7%
52W-Spanne
$12–$35
JANX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$10M2020-12-31 → 2025-12-31
EPS$-1.832021-12-31 → 2025-12-31
Freier Cashflow$-83M2021-12-31 → 2025-12-31
Nettogewinnmarge-427.5%2021-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | JANX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -10.35-Jahres-Durchschnitt ≈-16.1 | ≈-16.1 | · | · | |
| P/S (TTM) | 43.15-Jahres-Durchschnitt ≈146.2 | ≈146.2 | 12.6 | Überbewertet | |
| K/B (MRQ) | 1.15-Jahres-Durchschnitt ≈1.9 | ≈1.9 | 4.2 | Unterbewertet | |
| Kurs / FCF (TTM) | -24.75-Jahres-Durchschnitt ≈-29.2 | ≈-29.2 | · | · | |
| Kurs / Cashflow (TTM) | -25.15-Jahres-Durchschnitt ≈-30.6 | ≈-30.6 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 1.15-Jahres-Durchschnitt ≈1.9 | ≈1.9 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | JANX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -598.1%5-Jahres-Durchschnitt ≈-1019.5% | ≈-1019.5% | -329.2% | Im Einklang | |
| EBITDA Margin (EBITDA-Marge) | -1576.7%5-Jahres-Durchschnitt ≈-1019.5% | ≈-1019.5% | -329.2% | Im Einklang | |
| Nettogewinnmarge (TTM) | -427.5%5-Jahres-Durchschnitt ≈-827.9% | ≈-827.9% | -270.7% | Spitzenklasse | |
| ROA (TTM) | -10.1%5-Jahres-Durchschnitt ≈-13.9% | ≈-13.9% | -29.5% | Spitzenklasse | |
| ROE (TTM) | -10.7%5-Jahres-Durchschnitt ≈-13.0% | ≈-13.0% | -18.5% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | JANX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 16.35-Jahres-Durchschnitt ≈34.9 | ≈34.9 | 10.4 | Starke Liquidität | |
| Quick Ratio (MRQ) | 16.15-Jahres-Durchschnitt ≈34.6 | ≈34.6 | 2.5 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | JANX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | -5.5%5-Jahres-Durchschnitt ≈39.0% | ≈39.0% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 5.1% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | JANX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.0 | ≈0.0 | 0.3 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$88.5K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
14.8%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 11, 2026 | $-0.35 | $-0.39 | 10.7% |
| 31. März 2026 | Mai 12, 2026 | $-0.39 | $-0.54 | 27.4% |
| 31. Dezember 2025 | $-0.51 | $-0.66 | 22.4% | |
| 30. September 2025 | $-0.39 | $-0.63 | 38.1% | |
| 30. Juni 2025 | $-0.55 | $-0.48 | -15.5% | |
| 31. März 2025 | $-0.38 | $-0.40 | 5.5% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $8M | $9M | $4M | $0 | |
| R&D Expense | $126M | $68M | $55M | $53M | $26M | $3M | |
| SG&A Expense | $42M | $41M | $26M | $22M | $10M | $2M | |
| Operating Income | $-158M | $-99M | $-73M | $-67M | $-33M | $-5M | |
| Other Non-op | $44M | $30M | $15M | $4M | $257.0K | $-2M | |
| Income Tax | $0 | $0 | $0 | · | · | · | |
| Net Income | $-114M | $-69M | $-58M | $-63M | $-33M | $-7M | |
| EPS (Basic) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | · | |
| EPS (Diluted) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | · | |
| Shares (Basic) | 61,966,999 | 53,751,480 | 44,016,283 | 41,469,631 | 23,530,252 | 233,726 | |
| Shares (Diluted) | 61,966,999 | 53,751,480 | 44,016,283 | 41,469,631 | 23,530,252 | · | |
| EBITDA | $-158M | $-99M | $-73M | $-67M | $-33M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $52M | $431M | $19M | $51M | $36M | $8M | |
| Short-term Investments | $914M | $595M | $325M | $276M | $339M | $0 | |
| Receivables | $0 | · | $0 | $0 | $0 | $8M | |
| Prepaid Expense | $9M | $8M | $5M | $5M | $2M | $249.0K | |
| Current Assets | $976M | $1.03B | $349M | $332M | $377M | $16M | |
| PP&E (Net) | $4M | $5M | $7M | $7M | $1M | $155.0K | |
| PP&E (Gross) | $11M | $10M | $10M | $8M | $2M | $176.0K | |
| Accum. Depreciation | $7M | $5M | $3M | $972.0K | $131.0K | $21.0K | |
| Other Non-current Assets | $3M | $3M | $3M | $1M | $392.0K | $0 | |
| Total Assets | $1.00B | $1.06B | $380M | $364M | $380M | $16M | |
| Accounts Payable | $5M | $4M | $2M | $2M | $2M | $428.0K | |
| Accrued Liabilities | $18M | $12M | $7M | $8M | $4M | $751.0K | |
| Current Liabilities | $25M | $17M | $13M | $17M | $13M | $3M | |
| Capital Leases | $20M | $21M | $23M | $25M | $0 | $0 | |
| Total Liabilities | $45M | $39M | $36M | $43M | $13M | $9M | |
| Common Stock | $60.0K | $59.0K | $46.0K | $42.0K | $41.0K | $1.0K | |
| Retained Earnings | $-351M | $-238M | $-169M | $-110M | $-47M | $-15M | |
| AOCI | $4M | $2M | $665.0K | $-2M | $-270.0K | $0 | |
| Stockholders' Equity | $957M | $1.02B | $344M | $321M | $366M | $-15M | |
| Liabilities + Equity | $1.00B | $1.06B | $380M | $364M | $380M | $16M | |
| Shares Outstanding | 60,384,283 | 59,064,606 | 46,252,440 | 41,616,260 | 41,243,137 | 1,046,599 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $40M | $33M | $20M | $17M | $7M | $72.0K | |
| Deferred Tax | · | $0 | $0 | $0 | $0 | $0 | |
| Operating Cash Flow | $-82M | $-44M | $-51M | $-43M | $-17M | $-4M | |
| CapEx | $1M | $359.0K | $2M | $6M | $1M | $0 | |
| Investing Cash Flow | $-301M | $-258M | $-41M | $58M | $-341M | $0 | |
| Financing Cash Flow | $5M | $713M | $60M | $500.0K | $387M | $12M | |
| Free Cash Flow | $-83M | $-44M | $-52M | $-49M | $-18M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% | · | |
| Net Margin | -1136.2% | -651.6% | -721.2% | -732.2% | -898.3% | · | |
| EBITDA Margin | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% | · | |
| ROA | -11.0% | -9.6% | -15.7% | -17.0% | -16.5% | · | |
| ROE | -11.7% | -8.2% | -16.8% | -19.3% | -8.8% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 39.0 | 59.2 | 26.8 | 20.1 | 29.5 | · | |
| Quick Ratio | 38.7 | 58.7 | 26.4 | 19.8 | 29.3 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | · | · | · | · | 0.9 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $15.85 | $17.32 | $7.45 | $7.71 | $8.88 | · | |
| Revenue / Share | $0.16 | $0.20 | $0.18 | $0.21 | · | · | |
| Cash Flow / Share | $-1.33 | $-0.82 | $-1.15 | $-1.03 | · | · | |
| Cash / Share | $0.87 | $7.29 | $0.42 | $1.24 | $0.86 | · | |
| EPS (TTM) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | -5.5% | 31.0% | -6.1% | 136.8% | · | · | |
| Revenue CAGR 3Y | 5.1% | 42.8% | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $10M | $11M | $8M | $9M | $4M | · | |
| Net Income TTM | $-114M | $-69M | $-58M | $-63M | $-33M | · | |
| Market Cap | $833M | $3.16B | $496M | $548M | $814M | · | |
| P/E | -7.5 | -41.8 | -8.1 | -8.7 | -14.2 | · | |
| P/S | 83.3 | 298.7 | 61.4 | 63.6 | 223.7 | · | |
| P/B | 0.9 | 3.1 | 1.4 | 1.7 | 2.2 | · | |
| P / Tangible Book | 0.9 | 3.1 | 1.4 | 1.7 | 2.2 | · | |
| P / Cash Flow | -10.1 | -72.2 | -9.8 | -12.8 | -47.9 | · | |
| P / FCF | -10.0 | -71.6 | -9.5 | -11.1 | -44.1 | · | |
| Earnings Yield | -13.3% | -2.4% | -12.3% | -11.5% | -7.0% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $4M | $0 | $10M | $0 | $0 | $0 | $439.0K | $9M | $1M | $3M | $1M | $2M | $2M | $2M | $2M | |
| R&D Expense | $31M | $27M | $32M | $35M | $35M | $25M | $21M | $19M | $15M | $14M | $12M | $15M | $16M | $14M | $14M | $10M | |
| SG&A Expense | $11M | $11M | $11M | $11M | $10M | $10M | $8M | $18M | $8M | $7M | $6M | $7M | $6M | $6M | $6M | $5M | |
| Operating Income | $-32M | $-34M | $-42M | $-35M | $-45M | $-35M | $-29M | $-36M | $-14M | $-20M | $-16M | $-21M | $-20M | $-18M | $-17M | $-14M | |
| Other Non-op | $10M | $10M | $10M | $11M | $11M | $11M | $9M | $8M | $8M | $5M | $4M | $3M | $3M | $1M | $373.0K | $132.0K | |
| Net Income | $-22M | $-24M | $-32M | $-24M | $-34M | $-24M | $-20M | $-28M | $-6M | $-15M | $-12M | $-18M | $-17M | $-17M | $-17M | $-13M | |
| EPS (Basic) | $-0.35 | $-0.39 | $-0.51 | $-0.39 | $-0.55 | $-0.38 | $-0.36 | $-0.51 | $-0.11 | $-0.30 | $-0.25 | $-0.42 | $-0.42 | $-0.40 | $-0.41 | $-0.32 | |
| EPS (Diluted) | $-0.35 | $-0.39 | $-0.51 | $-0.39 | $-0.55 | $-0.38 | $-0.36 | $-0.51 | $-0.11 | $-0.30 | $-0.25 | $-0.42 | $-0.42 | $-0.40 | $-0.41 | $-0.32 | |
| Shares (Basic) | 62,937,295 | 62,665,717 | · | 62,023,685 | 61,902,411 | 61,791,721 | · | 54,628,670 | 54,451,666 | 49,049,741 | 45,708,649 | 41,836,238 | 41,763,971 | 41,526,524 | 41,448,743 | 41,315,482 | |
| Shares (Diluted) | 62,937,295 | 62,665,717 | · | 62,023,685 | 61,902,411 | 61,791,721 | · | 54,628,670 | 54,451,666 | 49,049,741 | 45,708,649 | 41,836,238 | 41,763,971 | 41,526,524 | 41,448,743 | 41,315,482 | |
| EBITDA | $-32M | $-34M | · | $-35M | $-45M | $-35M | · | $-36M | $-14M | $-20M | $-16M | $-21M | $-20M | $-18M | $-17M | $-14M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28M | $52M | $52M | $48M | $52M | $74M | $431M | $27M | $15M | $213M | $17M | $34M | $30M | $65M | $58M | $55M | |
| Short-term Investments | $943M | $905M | $914M | $941M | $944M | $940M | $595M | $631M | $632M | $439M | $333M | $270M | $287M | $274M | $296M | $306M | |
| Receivables | $149.0K | $35M | · | · | · | · | · | · | $8M | $519.0K | $0 | $0 | $750.0K | $500.0K | $0 | $0 | |
| Prepaid Expense | $12M | $11M | $9M | $9M | $10M | $9M | $8M | $8M | $8M | $6M | $5M | $6M | $4M | $5M | $4M | $3M | |
| Current Assets | $983M | $1.00B | $976M | $998M | $1.01B | $1.02B | $1.03B | $666M | $662M | $659M | $355M | $309M | $321M | $344M | $358M | $365M | |
| PP&E (Net) | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $6M | $7M | $7M | $7M | $7M | $7M | $4M | $3M | |
| PP&E (Gross) | $11M | $11M | $11M | $11M | $11M | $10M | $10M | $10M | $10M | $10M | $10M | $9M | $9M | $7M | $4M | $3M | |
| Accum. Depreciation | $8M | $7M | $7M | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $2M | $2M | $1M | $567.0K | $320.0K | $212.0K | |
| Other Non-current Assets | $3M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $207.0K | $337.0K | |
| Total Assets | $1.01B | $1.03B | $1.00B | $1.02B | $1.03B | $1.05B | $1.06B | $695M | $691M | $689M | $387M | $342M | $353M | $376M | $385M | $369M | |
| Accounts Payable | $3M | $3M | $5M | $3M | $3M | $2M | $4M | $2M | $1M | $2M | $3M | $2M | $2M | $3M | $3M | $2M | |
| Accrued Liabilities | $20M | $15M | $18M | $22M | $16M | $13M | $12M | $13M | $9M | $6M | $7M | $9M | $8M | $7M | $4M | $5M | |
| Current Liabilities | $60M | $59M | $25M | $28M | $21M | $18M | $17M | $17M | $12M | $11M | $14M | $18M | $16M | $16M | $13M | $13M | |
| Capital Leases | $18M | $19M | $20M | $20M | $20M | $21M | $21M | $22M | $22M | $23M | $23M | $24M | $24M | $24M | $23M | $0 | |
| Total Liabilities | $80M | $87M | $45M | $48M | $42M | $38M | $39M | $39M | $34M | $33M | $38M | $42M | $42M | $44M | $42M | $13M | |
| Common Stock | $61.0K | $60.0K | $60.0K | $60.0K | $59.0K | $59.0K | $59.0K | $52.0K | $52.0K | $51.0K | $46.0K | $42.0K | $42.0K | $42.0K | $42.0K | $41.0K | |
| Retained Earnings | $-398M | $-376M | $-351M | $-319M | $-295M | $-261M | $-238M | $-218M | $-189M | $-184M | $-157M | $-145M | $-128M | $-94M | $-78M | $-61M | |
| AOCI | $-2M | $576.0K | $4M | $5M | $4M | $4M | $2M | $8M | $-2M | $-524.0K | $-1M | $-1M | $-739.0K | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $928M | $942M | $957M | $977M | $991M | $1.01B | $1.02B | $656M | $658M | $656M | $349M | $299M | $311M | $332M | $344M | $356M | |
| Liabilities + Equity | $1.01B | $1.03B | $1.00B | $1.02B | $1.03B | $1.05B | $1.06B | $695M | $691M | $689M | $387M | $342M | $353M | $376M | $385M | $369M | |
| Shares Outstanding | 61,077,980 | 60,865,458 | 60,384,283 | 60,123,602 | 59,297,814 | 59,168,490 | 59,064,606 | 52,337,239 | 52,162,215 | 51,840,571 | 46,151,427 | 41,867,536 | 41,802,807 | 41,550,704 | 41,501,269 | 41,393,660 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $9M | $9M | $10M | $9M | $11M | $11M | $6M | $15M | $6M | $6M | $5M | $6M | $5M | $5M | $4M | $4M | |
| Operating Cash Flow | $12M | $-12M | $-29M | $-13M | $-24M | $-17M | $-17M | $-2M | $-10M | $-15M | $-12M | $-15M | $-14M | $-13M | $-6M | $-12M | |
| CapEx | $202.0K | $273.0K | $106.0K | $93.0K | $473.0K | $371.0K | $42.0K | $25.0K | $95.0K | $197.0K | $470.0K | $580.0K | $285.0K | $3M | $898.0K | $971.0K | |
| Investing Cash Flow | $-39M | $8M | $30M | $8M | $2M | $-340M | $34M | $13M | $-191M | $-114M | $-61M | $18M | $-9M | $20M | $9M | $31M | |
| Financing Cash Flow | $2M | $4M | $3M | $493.0K | $954.0K | $554.0K | $387M | $2M | $3M | $322M | $57M | $528.0K | $2M | $0 | $308.0K | $1.0K | |
| Free Cash Flow | · | $-13M | · | · | · | $-17M | · | · | · | $-15M | · | · | $-14M | · | · | $-12M |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -308.7% | -916.5% | · | -352.5% | · | · | · | -8164.5% | -155.4% | -1610.3% | -628.2% | -1962.9% | -990.3% | -994.0% | -729.9% | -852.2% | |
| Net Margin | -214.0% | -652.6% | · | -243.1% | · | · | · | -6391.6% | -67.0% | -1178.9% | -459.6% | -1656.4% | -852.5% | -920.9% | -714.1% | -843.9% | |
| EBITDA Margin | -308.7% | -916.5% | · | -352.5% | · | · | · | -8164.5% | -155.4% | -1610.3% | -628.2% | -1962.9% | -990.3% | -994.0% | -729.9% | -852.2% | |
| ROA | -2.1% | -2.3% | · | -2.8% | -3.9% | -2.7% | · | -5.2% | -1.1% | -2.8% | -3.0% | -4.8% | -4.8% | -4.3% | -4.3% | -7.3% | |
| ROE | -2.3% | -2.5% | · | -3.0% | -4.1% | -2.8% | · | -5.6% | -1.2% | -3.0% | -3.4% | -5.4% | -5.2% | -4.7% | -4.6% | -7.5% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 16.3 | 17.0 | · | 35.9 | 47.0 | 58.5 | · | 38.8 | 57.3 | 62.1 | 24.5 | 17.3 | 19.9 | 21.1 | 27.6 | 29.1 | |
| Quick Ratio | 16.1 | 16.8 | · | 35.5 | 46.6 | 57.9 | · | 38.3 | 56.6 | 61.5 | 24.2 | 16.9 | 19.7 | 20.8 | 27.3 | 28.9 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 2.7 | 0.2 | · | · | · | · | · | · | 2.4 | 2.0 | 10.1 | · | 5.5 | 7.3 | 12.6 | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $15.19 | $15.47 | · | $16.24 | $16.70 | $17.11 | · | $12.54 | $12.61 | $12.65 | $7.56 | $7.15 | $7.45 | $7.98 | $8.28 | $8.60 | |
| Revenue / Share | $0.16 | $0.06 | · | $0.16 | $0.00 | $0.00 | · | $0.01 | $0.16 | $0.03 | $0.06 | $0.03 | $0.05 | $0.04 | $0.06 | · | |
| Cash Flow / Share | · | $-0.20 | · | · | · | $-0.28 | · | · | · | $-0.30 | · | · | $-0.33 | · | · | · | |
| Cash / Share | $0.45 | $0.85 | · | $0.80 | $0.88 | $1.25 | · | $0.51 | $0.28 | $4.11 | $0.37 | $0.81 | $0.73 | $1.56 | $1.41 | $1.33 | |
| EPS (TTM) | $-1.64 | $-1.84 | · | $-1.68 | $-1.80 | $-1.36 | · | $-1.15 | $-0.89 | $-1.20 | $-1.48 | $-1.63 | $-1.62 | $-1.42 | $-1.28 | $-1.49 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $24M | $14M | · | $10M | $439.0K | $9M | · | $13M | $15M | $7M | $8M | $8M | $9M | $7M | $7M | $5M | |
| Net Income TTM | $-103M | $-114M | · | $-102M | $-106M | $-78M | · | $-61M | $-44M | $-56M | $-63M | $-68M | $-67M | $-60M | $-54M | $-44M | |
| Market Cap | $938M | $846M | · | $1.47B | $1.37B | $1.60B | · | $2.38B | $2.19B | $1.95B | $465M | $497M | $506M | $563M | $507M | $594M | |
| P/E | -9.4 | -7.6 | · | -14.5 | -12.8 | -19.9 | · | -39.5 | -47.1 | -31.4 | -6.8 | -7.3 | -7.5 | -9.5 | -9.5 | -9.6 | |
| P/S | 39.1 | 61.6 | · | 146.9 | 3120.2 | 171.1 | · | 182.2 | 144.4 | 267.8 | 54.9 | 64.0 | 55.8 | 76.2 | 75.3 | 122.5 | |
| P/B | 1.0 | 0.9 | · | 1.5 | 1.4 | 1.6 | · | 3.6 | 3.3 | 3.0 | 1.3 | 1.7 | 1.6 | 1.7 | 1.5 | 1.7 | |
| P / Tangible Book | 1.0 | 0.9 | · | 1.5 | 1.4 | 1.6 | · | 3.6 | 3.3 | 3.0 | 1.3 | 1.7 | 1.6 | 1.7 | 1.5 | 1.7 | |
| P / Cash Flow | · | -68.6 | · | · | · | -93.8 | · | · | · | -131.5 | · | · | -36.4 | · | · | -51.5 | |
| Earnings Yield | -10.7% | -13.2% | · | -6.9% | -7.8% | -5.0% | · | -2.5% | -2.1% | -3.2% | -14.7% | -13.7% | -13.4% | -10.5% | -10.5% | -10.4% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $10M | $11M | $8M | $9M | $4M |
| Betriebsgewinnmarge % | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% |
| Nettoergebnis | $-114M | $-69M | $-58M | $-63M | $-33M |
| Verwässerte EPS | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 39.0 | 59.2 | 26.8 | 20.1 | 29.5 |
| Quick Ratio | 38.7 | 58.7 | 26.4 | 19.8 | 29.3 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-83M | $-44M | $-52M | $-49M | $-18M |
Institutionelle Eigentümer (13F) 216 Einreicher · $1.0B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
216
Gehaltener Wert
$1.0B
Neue Positionen
40
Geschlossene Positionen
29
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 40 (-8 vs. Vorquartal) | 29 (+1 vs. Vorquartal) | 81 (+12 vs. Vorquartal) | 49 (-5 vs. Vorquartal) | +700K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $171.873.684 | 11.189.693 | 16,64% | Aktien |
| BlackRock, Inc. | $94.228.481 | 6.134.667 | 9,12% | Aktien |
| Prosight Management, LP | $58.436.828 | 3.804.481 | 5,66% | Aktien |
| JANUS HENDERSON GROUP PLC | $58.279.971 | 4.196.409 | 5,64% | Aktien |
| STATE STREET CORP | $46.155.249 | 3.004.899 | 4,47% | Aktien |
| VANGUARD GROUP INC | $40.108.126 | 2.906.386 | 3,88% | Aktien |
| FMR LLC | $37.060.986 | 2.412.825 | 3,59% | Aktien |
| FEDERATED HERMES, INC. | $36.140.959 | 2.352.927 | 3,50% | Aktien |
| Point72 Asset Management, L.P. | $30.625.336 | 1.993.837 | 2,97% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $28.528.911 | 1.857.351 | 2,76% | Aktien |
| TCG Crossover Management, LLC | $27.488.517 | 1.789.617 | 2,66% | Aktien |
| Alyeska Investment Group, L.P. | $25.300.070 | 1.647.140 | 2,45% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $23.153.049 | 1.507.360 | 2,24% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $20.439.706 | 1.330.710 | 1,98% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $18.543.360 | 1.207.250 | 1,80% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $18.499.798 | 1.204.150 | 1,79% | Aktien |
| CITADEL ADVISORS LLC | $18.443.321 | 1.200.737 | 1,79% | Aktien |
| ALGERT GLOBAL LLC | $17.063.255 | 1.110.889 | 1,65% | Aktien |
| D. E. Shaw & Co., Inc. | $16.842.378 | 1.096.509 | 1,63% | Aktien |
| GOLDMAN SACHS GROUP INC | $14.633.088 | 952.675 | 1,42% | Aktien |
| BANK OF AMERICA CORP /DE/ | $13.984.665 | 910.460 | 1,35% | Aktien |
| MORGAN STANLEY | $12.855.801 | 836.966 | 1,24% | Aktien |
| Nantahala Capital Management, LLC | $12.440.279 | 809.914 | 1,20% | Aktien |
| Qube Research & Technologies Ltd | $10.783.596 | 702.057 | 1,04% | Aktien |
| Squarepoint Ops LLC | $8.176.451 | 532.321 | 0,79% | Aktien |
| ORBIMED ADVISORS LLC | $8.059.392 | 524.700 | 0,78% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $7.749.796 | 504.544 | 0,75% | Aktien |
| ADAR1 Capital Management, LLC | $6.464.732 | 420.881 | 0,63% | Aktien |
| Cubist Systematic Strategies, LLC | $6.293.960 | 257.527 | 0,61% | Aktien |
| NORTHERN TRUST CORP | $6.118.902 | 398.366 | 0,59% | Aktien |
| JANE STREET GROUP, LLC | $6.020.981 | 391.991 | 0,58% | Aktien |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $5.782.979 | 376.496 | 0,56% | Aktien |
| Woodline Partners LP | $5.683.692 | 370.032 | 0,55% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $5.670.774 | 369.191 | 0,55% | Aktien |
| Rock Springs Capital Management LP | $5.637.258 | 367.009 | 0,55% | Aktien |
| Jump Financial, LLC | $5.555.174 | 361.665 | 0,54% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $5.525.376 | 359.725 | 0,54% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $4.842.563 | 315.271 | 0,47% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $4.133.576 | 269.113 | 0,40% | Aktien |
| Man Group plc | $3.821.583 | 248.801 | 0,37% | Aktien |
| Balyasny Asset Management L.P. | $3.250.714 | 211.635 | 0,31% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $3.219.348 | 209.593 | 0,31% | Aktien |
| Y-Intercept (Hong Kong) Ltd | $3.018.040 | 196.487 | 0,29% | Aktien |
| JPMORGAN CHASE & CO | $2.736.049 | 178.535 | 0,26% | Aktien |
| Allspring Global Investments Holdings, LLC | $2.434.909 | 166.092 | 0,24% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2.403.840 | 156.500 | 0,23% | Verkaufsoption |
| BML Capital Management, LLC | $2.380.201 | 154.961 | 0,23% | Aktien |
| UBS Group AG | $2.314.767 | 150.701 | 0,22% | Aktien |
| Springhill Fund Asset Management (HK) Co Ltd | $2.119.500 | 78.500 | 0,21% | Aktien |
| Bank of New York Mellon Corp | $2.074.706 | 135.072 | 0,20% | Aktien |
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×5 Einreichungen | 10. März 2025 | 19,90% | Änderung | · | SEC |
| Avalon Ventures XI, L.P., Avalon BioVentures SPV I, L.P., Avalon BioVentures I, LP, Avalon Ventures XI GP LLC, ABV SPV I GP LLC, Avalon BioVentures GP, LLC, Kevin Kinsella, Richard Levandov, Braden Bohrmann, Jay Lichter, Ph.D., Tighe Reardon, Sergio G. Duron, Ph.D., Sanford Madigan, Ph.D. ×6 Einreichungen | 8. November 2024 | · | Erste Einreichung | · | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP VIII LLC, OrbiMed Genesis GP LLC, OrbiMed Capital LLC ×3 Einreichungen | 9. August 2024 | · | Erste Einreichung | · | SEC |
| Avalon Ventures XI, L.P. (“Avalon Ventures”), Avalon BioVentures SPV I, L.P. (“ABV SPV”), Avalon Bioventures I, LP (“ABV I”), Avalon Ventures XI GP LLC (“Avalon XI GP”), ABV SPV I GP LLC (“ABV SPV GP”), Avalon BioVentures GP, LLC (“ABV GP”), Kevin Kinsella (“Kinsella”), Richard Levandov (“Levandov”), Braden Bohrmann (“Bohrmann”), Jay Lichter, Ph.D. (“Lichter”), Tighe Reardon (“Reardon”), Sergio Duron (“Duron”), Sanford Madigan, Ph.D. (“Madigan”) ×2 Einreichungen | 16. November 2023 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 24 Insider · 12 Führungskräfte · 11 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| David Alan Campbell | President and CEO | 31. Juli 2026 G | 264.742 | 0 | 1 | $-110.829 |
| Tighe Reardon | Acting Chief Financial Officer | 3. Juni 2024 S | 3.340.018 | 0 | 0 | $0 |
| Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | 2. Juni 2026 S | 75.941 | 0 | 1 | $-56.948 |
| Maria Dobek | Vice President, Accounting | 11. Mai 2026 S | 32.270 | 0 | 2 | $-48.951 |
| William Go | Chief Medical Officer | 2. Februar 2026 A | 44.000 | 0 | 0 | $0 |
| Zachariah Mciver | Chief Medical Officer | 2. Januar 2026 A | 52.286 | 0 | 1 | $-37.263 |
| Thomas Diraimondo | Chief Scientific Officer | 2. Januar 2026 A | 155.825 | 0 | 1 | $-34.394 |
| Charles M. Winter | Chief Technical Officer | 2. Januar 2026 A | 106.321 | 0 | 1 | $-32.966 |
| Andrew Hollman Meyer | Chief Business Officer | 2. Januar 2026 S | 83.095 | 0 | 5 | $-736.652 |
| Byron Robinson | Chief Strategy Officer | 2. Januar 2025 A | 28.000 | 0 | 0 | $0 |
| Wayne Godfrey | Chief Medical Officer | 3. Januar 2023 A | · | 0 | 0 | $0 |
| Shahram Salek-Ardakani | Chief Scientific Officer | 3. Januar 2022 A | · | 0 | 0 | $0 |
| Jake Simson | Direktor | 11. Juni 2026 A | 11.750 | 0 | 0 | $0 |
| Natasha Hernday | Direktor | 11. Juni 2026 A | 15.481 | 0 | 0 | $0 |
| Winston Kung | Direktor | 11. Juni 2026 A | 11.750 | 0 | 0 | $0 |
| Ronald W Barrett | Direktor | 11. Juni 2026 A | 11.750 | 0 | 0 | $0 |
| Vickie L Capps | Direktor | 11. Juni 2026 A | 79.598 | 0 | 0 | $0 |
| Eric Dobmeier | Direktor | 11. Juni 2026 A | 15.481 | 0 | 0 | $0 |
| Alana B. Mcnulty | Direktor | 11. Juni 2025 A | 6.250 | 0 | 0 | $0 |
| Sheila Gujrathi | Direktor | 11. Juni 2025 A | 118.889 | 0 | 0 | $0 |
| Stefan Heller | Direktor | 14. Juni 2022 A | · | 0 | 0 | $0 |
| Peter A. Thompson | Direktor | 14. Juni 2022 A | 231.098 | 0 | 0 | $0 |
| Jay Lichter | 10%-Eigentümer | 13. September 2024 M | 7.000 | 0 | 0 | $0 |
| Bregua Corp | 10%-Eigentümer | 15. Juni 2021 C | 3.749.250 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 29 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IDNA · iShares Trust | 0,98% | 142.050 SH | 11. September 2026 | Täglich |
| BBC · ETFis Series Trust I | 0,75% | 22.923 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,20% | 65.529 NS | 31. Juli 2026 | N-PORT |
| ESSC · Strategy Shares | 0,12% | 2.826 NS | 31. Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,07% | 435.895 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,07% | 4.350 SH | 2. Oktober 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,06% | 895 NS | 31. Juli 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,04% | 37.644 SH | 19. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 47.185 SH | 2. Oktober 2026 | Täglich |
| FBCG · FIDELITY COVINGTON TRUST | 0,03% | 123.298 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,03% | 1.107.172 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,02% | 20.662 NS | 31. Juli 2026 | N-PORT |
| TECB · iShares Trust | 0,02% | 5.624 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 248.060 SH | 19. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,01% | 123.038 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 552.164 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 117.899 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 18.188 NS | 31. Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2.569 SH | 11. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,00% | 5.688 NS | 31. Juli 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,00% | 1.318 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 68.785 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 13.661 SH | 11. September 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.263.837 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.110 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 402.945 SH | 11. September 2026 | Täglich |
| ISCB · iShares Trust | · | 2.013 SH | 11. September 2026 | Täglich |
| ISCV · iShares Trust | · | 9.972 SH | 11. September 2026 | Täglich |
| SMLF · iShares Trust | · | 53.769 SH | 11. September 2026 | Täglich |
JANX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 26 Analysten
KAUF
Median-Ziel
$29.00
+71,3%
10 38,5%
Starker Kauf
12 46,2%
Kauf
3 11,5%
Halten
1 3,8%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
17 Analysten · 2026-09-28Mittelwert-Ziel $36.24 +114,0%
Jetzt
Aktueller Preis $16.93
Tief$14.00
Mittelwert$36.24
Hoch$75.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | · |
| BCAX | $953M | -6.7 | · | · | -33.0% | · |
| TRAX | · | · | · | · | · | · |
| VOR | $506M | -0.2 | · | · | 83.4% | · |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | · |
| AKTS | · | · | · | · | · | · |
| ODTX | · | · | · | · | · | · |
| SVRA | $1.23B | -11.4 | · | · | -73.4% | · |
| KURA | $913M | -3.3 | 25.2% | -413.0% | -116.2% | · |
| CGEM | $624M | -3.2 | · | · | -44.0% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026